key: cord-0714338-uh0quk2t
authors: Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad
title: The effect of higher-intensity-dosing anticoagulation in the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials
date: 2021-11-17
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.11.008
sha: d9c9df345550e85d686c3ed23df96dc9252caaff
doc_id: 714338
cord_uid: uh0quk2t

OBJECTIVE: We aimed to perform a meta-analysis to summarize the overall evidence from randomized controlled trials related to higher-intensity anticoagulation in hospitalized patients with COVID-19. METHODS: A systematic literature search was performed in electronic databases to identify randomized controlled trials comparing the clinical outcomes between intermediate or therapeutic anticoagulation and prophylactic anticoagulation. Meta-analyses with random-effects models were used to estimate the pooled odds ratio (OR) for outcomes of interest at a 95% confidence interval (CI). RESULTS: Eight randomized controlled trials were included, with a total of 5405 hospitalized patients with COVID-19. The meta-analysis revealed no statistically significant difference in the odds of mortality (pooled OR = 0.92; 95% CI 0.71–1.19) but a statistically significant reduction in the odds of development of thrombotic events (pooled OR = 0.55; 95% CI 0.42–0.72), and significantly increased odds of development of major bleeding (pooled OR = 1.81; 95% CI 1.20–2.72) with the use of intermediate/therapeutic anticoagulation relative to prophylactic anticoagulation, with adequate evidence against our model hypothesis of “no significant difference”, at the current sample size. Subgroup analysis in patients with a severe course of COVID-19 observed a statistically significant reduction in the odds of development of thrombotic events (pooled OR = 0.66; 95% CI 0.45–0.98) but no significant difference in the odds of development of major bleeding events (pooled OR = 1.37; 95% CI 0.74–2.56), with the use of intermediate/therapeutic anticoagulation relative to prophylactic anticoagulation. CONCLUSION: There were net clinical benefits with higher-intensity-dosing anticoagulation relative to prophylactic-dosing anticoagulation among hospitalized patients with severe COVID-19.

The recognition of a hypercoagulable state in patients with coronavirus disease 2019 (COVID- 19) , including elevated levels of factor VIII and fibrinogen and formation of neutrophil extracellular traps, has led to the utilization of venous thromboembolism (VTE) prophylaxis. However, about 38% of hospitalized patients with a severe course of COVID-19 still developed VTE [1] . Therefore, there have been recommendations to use higher-intensity (rather than prophylactic dosing) parenteral anticoagulants to further reduce VTE risk in patients with a severe course of COVID-19. However, some clinicians are reluctant for higher-intensity dosing due to the fear of bleeding events, which might outweigh the uncertain benefits. More clinical evidence is undoubtedly needed to resolve the dispute.

There have been attempts to trial the use of higher-intensity dosing of parenteral anticoagulant in hospitalized patients with COVID-19 relative to prophylactic-dosing. However, a recent systematic review and meta-analysis [2] of 38 observational studies reported that patients who received prophylactic anticoagulation had significantly better survival (odds ratio = 0.65, 95% confidence interval 0.46 to 0.91) and significantly reduced risk of bleeding (odds ratio = 0.31, 95% confidence interval 0.21 to 0.45) compared to their counterparts treated with therapeutic anticoagulation, but with no significant difference in the risk of thromboembolism (odds ratio = 1.03, 95% confidence interval 0.70 to 1.49) and was associated with a significantly higher risk of bleeding. While their findings seem to argue against the use of therapeutic anticoagulation in patients with COVID-19, observational studies are notoriously vulnerable to the effect of confounding bias, and clinical evidence with higher quality is required.

Randomized controlled trials are the gold standard for studying causal relationships between interventions and outcomes. Therefore, we aimed to perform a meta-analysis to summarize the overall evidence from randomized controlled trials related to using higher-intensity dosing of parenteral anticoagulant in hospitalized patients with J o u r n a l P r e -p r o o f Methods This study was conducted according to the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [3] . A systematic literature search with no language restriction was performed in electronic databases, including PubMed, Google Scholar, Cochrane Central Register of Controlled Trials, and preprint servers (medRxiv, Research Square, SSRN), to identify eligible studies, published up to October 11, 2021. The search strategy was built based on the following keywords and MeSH terms: "COVID-19", "SARS-CoV-2", "anticoagulant", "anticoagulation", "heparin", and "randomized". The clinical trial registries of the United States (clinicaltrials.gov) and the World Health Organization international (who.int/clinical-trials-registry-platform) were also searched to identify clinical trials with released findings. In addition, the reference lists of relevant articles were also reviewed to search for additional studies. Studies eligible for inclusion were randomized controlled trials comparing the clinical outcomes between higher-intensity anticoagulation (either intermediate or therapeutic anticoagulation) and prophylactic anticoagulation in hospitalized patients with COVID-19. We excluded studies with observational design, single-arm trials, non-randomized trials, and trials that did not report clinical outcomes of interest.

Two investigators (CSK and SSH) independently performed the literature screening, screened titles and abstracts, and thoroughly evaluated full-texts to identify potentially eligible studies. Any conflicts in the selection of studies were resolved through mutual discussion and consulting with a third investigator. The outcomes of interest were all-cause mortality, thrombotic events, and major bleeding events. Two investigators (CSK and SSH) independently evaluated each trial, who extracted the study characteristics using a pre-designed data abstraction form. Study characteristics extracted included the first author's surname, trial design, country, age of patients, the definition of severe course of illness, J o u r n a l P r e -p r o o f intermediate/therapeutic anticoagulation regimen, prophylactic anticoagulation, and all-cause mortality VTE major bleeding events.

Two investigators (CSK and SSH) assessed the risk of bias of the trials included with Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) [4] . The overall risk of bias for each trial was categorized as low if the risk of bias was low in all domains, some concern if the risk of bias was deemed to have some concern in at least one domain and with no high risk of bias in any domain, or high if the risk of bias was high in at least one domain, as per the RoB 2 tool. Disagreements were resolved through mutual discussion and consulting with a third investigator if necessary.

Meta-analyses with the random-effects model were used considering the potential heterogeneity across different studies to estimate the pooled odds ratio for outcomes of interest using intermediate/therapeutic anticoagulation relative to prophylactic anticoagulation at 95% confidence intervals. Random-effects meta-analysis involves a process whereby the inverse variance weighting of the fixed model is reversed to a variable extent. We examined the heterogeneity between studies using the I 2 statistics and the χ 2 test, with significant heterogeneity at 50% and p<0.10. Subgroup analysis was conducted to investigate the robustness of the results by including trials that examined the effect of therapeutic anticoagulation relative to prophylactic anticoagulation on the outcomes of interest.

Publication bias was analyzed using visual inspection of funnel plot for asymmetry with the help of a triangle centred on a fixed effect summary estimate and extending 1.96 standard errors on either side.

Subgroup analysis was conducted across trials that recruited only patients with a severe course of COVID-19. All analyses were performed using Meta XL, version 5.3 (EpiGear International, Queensland, Australia).

The default option of MetaXL software, DerSimonian and Laird method, was used to run the randomeffects model of meta-analysis.

Our systematic literature search retrieved 1881 hits, of which 1045 were unique (titles retrieved after removing duplications). After screening against inclusion and exclusion criteria, eight randomized controlled trials [5] [6] [7] [8] [9] [10] [11] [12] were included (Figure 1) , with a total of 5,405 patients (2,746 patients randomized to the intermediate or therapeutic anticoagulation group, and 2,659 patients randomized to the prophylactic anticoagulation group). Four of the included randomized trials in this systematic review and meta-analysis were from Iran (n=1) [7] , the United States (n=2) [8, 12] , and Brazil (n=2) [5, 9] , respectively, and one of the included randomised trial [11] was a global trial performed in six countries. In contrast, the remaining two randomized trials [6, 10] were international multiplatform randomized controlled trials. Table 1 . Six randomized trials [5, 6, [9] [10] [11] [12] The overall risk of bias assessed by RoB 2 is presented in Table 1 . Except for the trial by Spyropoulos et al. [12] , which had an overall low risk of bias, the remaining included trials had some concerns over the overall risk of bias. Both the trials by Lemos et al. [5] and Sholzberg et al. [11] , respectively, had some concerns of bias for the domain of randomization due to a lack of information on allocation concealment J o u r n a l P r e -p r o o f Sensitivity analysis of randomized trials [5, 6, [9] [10] [11] [12] which investigated the effect of therapeutic anticoagulation relative to prophylactic anticoagulation in hospitalized patients with COVID-19 revealed consistent findings with the main analysis; there was a statistically significant reduction in the odds of development of thrombotic events (Figure S1 ; pooled odds ratio = 0.50; 95% confidence interval 0.37 to 0.66), and significantly increased odds in the development of major bleeding events (Figure S1 ; pooled odds ratio = 1.86; 95% confidence interval 1.19 to 2.90), but with no statistically significant difference in the odds of mortality (Figure S1 ; pooled odds ratio = 0.88; 95% confidence interval 0.62 to 1.25). Subgroup analysis of randomized trials [5] [6] [7] [8] 

To the best of the authors' knowledge, this is the first systematic review and meta-analysis to summarize the overall evidence from randomized controlled trials related to higher-intensity anticoagulation in hospitalized patients with COVID-19. The findings from our meta-analyses of randomized controlled trials indicate benefits about the risk reduction of development of thrombotic events using higher-intensitydosing of parenteral anticoagulant in hospitalized patients with COVID-19, relative to prophylactic-dosing, which coincide with several real-world observations which adjusted for confounding bias. Recently, the J o u r n a l P r e -p r o o f retrospective study by Carallo et al. [13] (n=42) reported significantly reduced hazard for the combined cardiovascular endpoint of deep venous thrombosis, myocardial infarction, pulmonary embolism, and cardiovascular death (hazard ratio = 0.21; 95% confidence interval 0.05 to 0.93) with higher-intensity anticoagulation compared to lower-intensity anticoagulation, after adjustment of covariates, among hospitalized patients with COVID-19. Likewise, Helms et al. [14] (n = 179) reported in their prospective study that the occurrences of pulmonary embolism and deep vein thrombosis were significantly lower with therapeutic anticoagulation (adjusted odds ratio = 0.19; 95% confidence interval 0.03 to 0.81 and adjusted odds ratio = 0.13; 95% confidence interval 0.01 to 0.89, respectively) compared to prophylactic anticoagulation, but without significant difference between the two anticoagulation approaches in the mortality rate.

The reduced risk of developing thrombotic events with higher-intensity-dosing anticoagulation might be related to the phenomenon of heparin resistance (the requirement for high doses of heparin to achieve therapeutic activity) in patients with a severe course of COVID-19, which had been reported in a few observational studies [15, 16] . Yet, the significantly increased risk of major bleeding detected from our meta-analysis could be a concern for the clinicians since it indicates that the harms of higher-intensity anticoagulation, especially major bleeding, probably outweigh its benefits among hospitalized patients with COVID-19. However, with an assumed control risk of 0.062 (the incidence of development of thrombotic event in the control group was 62 per 1000), an estimated 37 patients would require administration of higher-intensity-dosing anticoagulation to prevent one thrombotic event. On the other hand, with an assumed control risk of 0.014 (the frequency of major bleeding in the control group was 14 per 1000), an estimated 90 patients would require administration of higher-intensity-dosing anticoagulation to experience one major bleeding event. Therefore, the benefits from risk reduction of development of thrombotic events with higher-intensity-dosing anticoagulation have the potential to J o u r n a l P r e -p r o o f outweigh its risks of major bleeding, relative to prophylactic-dose anticoagulation, among hospitalized patients with COVID-19.

It should be noted that the baseline risks of bleeding of the included participants were not assessed in the included trials [5] [6] [7] [8] [9] [10] [11] [12] . Therefore, the acceptable baseline risk of bleeding remains to be determined among hospitalized patients with COVID-19, which would lead to net clinical benefit with higher-intensity-dosing anticoagulation. Nevertheless, patients with a severe course of COVID-19 had no increased risk of major bleeding as per our subgroup analysis; this could be explained again by the phenomenon of heparin resistance, which may be more pronounced in patients with severe illness relative to mild-to-moderate illness. Hence, higher-intensity-dosing anticoagulation could be administered only in the subgroup of patients with severe illness (e.g., admission into intensive care units), with cognizant of the potentially favorable risk-benefit profile of higher-intensity anticoagulation among patients with low bleeding risks.

Furthermore, we advise an individualized anticoagulation approach for patients with high bleeding risks (e.g., history of major bleeding) since this subgroup of patients had been excluded from the clinical trials.

The absence of mortality benefits based on our meta-analysis suggests that the initiation of higherintensity anticoagulation when patients with COVID-19 progress to a severe course of illness might be too late to contain the effect of established thrombo-inflammation adequately; the use of anti-inflammatory therapies with established mortality benefits should still be the mainstay in this patient population [17] .

Again, it indicates that the use of higher-intensity anticoagulation in patients with a mild-to-moderate course of COVID-19 might not be associated with a favorable risk-benefit ratio, particularly in the context of antiviral therapies such as remdesivir [18] , which could retard the progression of the disease. However, more evidence from clinical trials is required. In addition, the development of thrombotic events is only part of the disease pathophysiology in patients with COVID-19 that leads to mortality, and much of the mortality has been associated with the cytokine storm syndrome and subsequent multiorgan failures associated with COVID-19 [19, 20] .

Limitations of our systematic review and meta-analysis should be acknowledged; firstly, all the included trials [5] [6] [7] [8] [9] [10] [11] [12] had an open-label design, and thus bias in the ascertainment of outcomes, especially of thrombotic events, cannot be excluded, and future double-blind, randomized controlled trials should substantiate the current findings; secondly, the majority of the included trials [5] [6] [7] [8] [9] [10] [11] [12] enrolled a relatively small number of participants and with limited heterogeneity across the included trials. Thus the possibility of a small mortality benefit cannot be confidently excluded, which should be confirmed in future largerscale randomized controlled trials. Thirdly, due to the availability of limited trials, we could not perform subgroup analysis across trials that administered intermediate-dosing anticoagulation to the intervention group. Lastly, we did not prepare and register our study protocol in PROSPERO which is typically recommended for systematic reviews and meta-analyses.

In conclusion, there were net clinical benefits with administering higher-intensity-dosing anticoagulation relative to prophylactic-dosing anticoagulation among hospitalized patients with COVID-19, especially those with severe course of illness. Routine screening of bleeding risk may facilitate the clinical judgement on the intensity of anticoagulation to be administered in an individual patient hospitalized with COVID-

Funding: No external funding was used in the preparation of this manuscript.

All authors declare that they have no potential conflicts of interest that might be relevant to the contents of this article.

Data availability: The data presented in this study are available in the manuscript.

Author and co-author contribution: Chia Siang Kow and Dinesh Sangarran Ramachandram were involved in study design, execution, analysis, manuscript drafting, and discussion. Syed Shahzad Hasan was involved in study design, analysis, and manuscript drafting.

Author acknowledgement: Not applicable Consent to publication: All authors consent for publication. 

Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis

Clinical Outcomes of Prophylactic vs. Therapeutic Doses of Anticoagulation In COVID-19 Patients: A Systematic Review and Metaanalysis

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

RoB 2: a revised tool for assessing risk of bias in randomised trials

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Intermediate vs Standard-dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to ICU: Ninety-day Results from the INSPIRATION Trial

Standard Prophylactic Versus Intermediate Dose Enoxaparin in Adults with Severe COVID-19: A Multi-Center

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an openlabel, multicentre, randomised, controlled trial

ATTACC Investigators; ACTIV-4a Investigators

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Heparin for Moderately Ill Patients with Covid-19

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia

Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study

Heparin resistance in COVID-19 patients in the intensive care unit

Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Effect of remdesivir on mortality in patients with COVID-19: A metaanalysis of randomized control trials

Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review

Cytokine signatures of end organ injury in COVID-19

J o u r n a l P r e -p r o o f 21